Table 1 Baseline characteristics in persistent AF patients with CHAD2DS2-VASc scores ≤ 2 and ≥ 3
CHAD2DS2-VASc score ≤ 2 (n = 80) | CHAD2DS2-VASc score ≥ 3 (n = 58) | P value | |
|---|---|---|---|
Age, years | 62 (56.75-67) | 70 (65–74) | < 0.01 |
Female sex, n (%) | 13 (16.25%) | 28 (48.28%) | < 0.01 |
CHA2DS2-VASc score, n | 1.26 (0.72) | 3.78 (0.9) | < 0.01 |
HAS BLED score, n | 0.81 (0.71) | 1.9 (0.83) | < 0.01 |
BMI, kg/m² | 29.1 (26.9–32) | 30.4 (25.9–32.9) | 0.45 |
Hypertension, n (%) | 35 (43.75%) | 51 (87.93%) | < 0.01 |
Diabetes mellitus, n (%) | 4 (5%) | 22 (37.93%) | < 0.01 |
Dyslipidemia, n (%) | 22 (27.5%) | 28 (48.28%) | 0.02 |
OSA, n (%) | 23 (28.75%) | 19 (32.76%) | 0.75 |
eGFR, ml/min/1,73² | 89 (74.75-95) | 71 (60-89.5) | < 0.01 |
Coronary artery disease, n (%) | 10 (12.5%) | 5 (8.62%) | 0.66 |
Time to treatment, days | 702 (197–1531) | 620 (240–1848) | 0.96 |
Reported AF duration, months | 0.09 | ||
< 3 months | 62 (78.48%) | 79.31% (46) | |
≥ 3 to < 6 months | 11 (13.92%) | 4 (6.9%) | |
≥ 6 to < 9 months | 2 (2.53%) | 7 (12.07%) | |
≥ 9 to < 12 months | 2 (2.53%) | 0 (0%) | |
≥ 12 months | 2 (2.53%) | 1 (1.72%) | |
Thromboembolism, n (%) | 2 (2.5%) | 14 (24.14%) | < 0.01 |
P-wave duration ≥ 150 ms, n (%) | 24 (30%) | 31 (54.39%) | < 0.01 |
LVEF, % before ablation | 61 (51–67) | 58 (47-64.25) | 0.26 |
Per-procedural LAIV excluding LAA, ml | 132.5 (110-151.3) | 130 (117.5–150) | 0.87 |
Per-procedural LAIVI excluding LAA, ml.m2 | 62.6 (53.2–68.6) | 64.8 (56–74) | 0.13 |
Beta-blocker | 65 (81.25%) | 50 (86.21%) | 0.59 |
ACEi/ARB | 45 (56.25%) | 41 (70.69%) | 0.12 |
Aldosterone receptor antagonist | 12 (15%) | 17 (29.31%) | 0.07 |